Cellectar Biosciences Announces up to Approximately $103 Million Private Placement FinancingGlobeNewsWire • 09/05/23
Cellectar Reports Financial Results for Second Quarter 2023 and Provides a Corporate UpdateGlobeNewsWire • 08/14/23
Is Cellectar Biosciences (CLRB) Outperforming Other Medical Stocks This Year?Zacks Investment Research • 06/30/23
Cellectar Biosciences Highlights Promising Interim Data from Its Ongoing Study of Iopofosine I 131 in Multiple Myeloma in an Oral Presentation at the SNMMI Annual MeetingGlobeNewsWire • 06/28/23
UPDATE -- Cellectar Reports Financial Results for First Quarter 2023 and Provides a Corporate UpdateGlobeNewsWire • 05/04/23
Cellectar Reports Financial Results for First Quarter 2023 and Provides a Corporate UpdateGlobeNewsWire • 05/04/23
Cellectar Reports Financial Results for Year Ended 2022 and Provides a Corporate UpdateGlobeNewsWire • 03/09/23
Cellectar Biosciences Reports Complete Response in a Relapsed/Refractory CNS Lymphoma PatientGlobeNewsWire • 02/28/23
Cellectar Biosciences Hires Dr. Andrei Shustov as New Senior Vice President, MedicalGlobeNewsWire • 02/15/23
Cellectar Biosciences Announces Presentation of Data on CLR 12120 Series of Targeted Alpha-Emitting Therapies at the 13th Annual World ADC ConferenceGlobeNewsWire • 11/21/22
Cellectar Announces Resolution of Breach of Contract and Intellectual Property DisputeGlobeNewsWire • 11/16/22
Cellectar Reports Financial Results for Third Quarter 2022 and Provides a Corporate UpdateGlobeNewsWire • 11/03/22
Cellectar Biosciences Announces Closing of Concurrent Registered Direct and Private Placement Offerings of Approximately $10.7 Million Priced At-The-Market Under Nasdaq RulesGlobeNewsWire • 10/25/22
Cellectar Biosciences Announces Concurrent Registered Direct and Private Placement Offerings of Approximately $10.7 Million Priced At-The-Market Under Nasdaq RulesGlobeNewsWire • 10/21/22
Cellectar Awarded $2 Million Grant to Expand Its Ongoing Phase 1 Study of Iopofosine I 131 in Pediatric Brain TumorsGlobeNewsWire • 09/22/22
Cellectar Announces Publication of Data from Its Expansion Cohort of the Phase II CLOVER-1 Study Iopofosine I-131 in Relapsed/Refractory Multiple Myeloma in Nature's Blood Cancer JournalGlobeNewsWire • 09/13/22
Cellectar Reports Financial Results for First Quarter 2022 and Provides a Corporate UpdateGlobeNewsWire • 05/10/22
Cellectar Reports Financial Results for Year Ended December 2021 and Provides a Corporate UpdateGlobeNewsWire • 03/21/22